secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunoGen, Inc. (—)
CIK:        0000855654
Form:       8-K
Filed at:   2023-04-06T23:59:59+00:00
Accession:  0001558370-23-005515
Event type: debt
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmunoGen secures up to $175M non-dilutive term loan from Pharmakon; $75M drawn at close
--------------------------------------------------------------------------------

- Initial tranche of $75M funded immediately; second tranche of $50M (expandable to $100M) contingent on MIRASOL trial data and ELAHERE sales threshold.
- Loan matures April 2028; interest-only for 36 months (extendable 12 months), then ratable principal payments.
- Interest rate: 3-month SOFR (floor 2.75%) + 8.00% per annum.
- Proceeds used for general corporate and working capital; loan secured by substantially all assets except certain non-ELAHERE IP.
- Goldman Sachs acted as financial advisor to ImmunoGen on the transaction.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/855654/000155837023005515/0001558370-23-005515-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/855654/000155837023005515/imgn-20230406x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-005515

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer